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A B S T R A C T
Background: Styrene is an established neurotoxicant at occupational levels, but effects at levels relevant to the
general population have not been studied. We examined the neurologic effects of environmental styrene ex-
posure among U.S. Gulf coast residents.
Methods: We used National Air Toxics Assessment (NATA) 2011 estimates of ambient styrene concentrations to
assign exposure levels for 21,962 non-diabetic Gulf state residents, and additionally measured blood styrene
concentration in a subset of participants (n= 874). Neurologic symptoms, as well as detailed covariate in-
formation, were ascertained via telephone interview. We used log-binomial regression to estimate prevalence
ratios (PR) and 95% confidence intervals (95% CI) for cross-sectional associations between both ambient and
blood styrene levels and self-reported neurologic symptoms. We estimated associations independently for ten
unique symptoms, as well as for the presence of any neurologic, central nervous system (CNS), or peripheral
nervous system (PNS) symptoms. We also examined heterogeneity of associations with estimated ambient
styrene levels by race and sex.
Results: One-third of participants reported at least one neurologic symptom. The highest quartile of estimated
ambient styrene was associated with one or more neurologic (PR, 1.12; 95% CI: 1.07,1.18), CNS (PR, 1.17; 95%
CI: 1.11,1.25), and PNS (PR, 1.16; 95% CI: 1.09,1.25) symptom. Results were less consistent for biomarker
analyses, but blood styrene level was suggestively associated with nausea (PR, 1.78; 95% CI: 1.04, 3.03). In
stratified analyses, we observed the strongest effects among non-White participants.
Conclusions: Increasing estimated ambient styrene concentration was consistently associated with increased
prevalence of neurologic symptoms. Associations between blood styrene levels and some neurologic symptoms
were suggestive. Environmental styrene exposure levels may be sufficient to elicit symptomatic neurotoxic ef-
fects.
1. Introduction
Styrene is a hydrocarbon used in the production of plastics, fi-
berglass laminates, rubber, and resins found in consumer products and
commercial and residential building materials. Manufactured styrene
products include insulation, fiberglass boats, automotive parts, car
tires, Styrofoam, and plastic drinking glasses (ATSDR, 2010). Styrene is
an established neurotoxicant at occupational levels (ATSDR, 2010;
CDC, 1978; IARC, 2002), but has not been studied at environmental
levels experienced outside of occupational contexts. Epidemiologic
studies to date have focused on highly exposed workers, whose average
blood concentrations are 25 times higher than those of the general
population (Brugnone et al., 1993; Coggon, 1994; Cherry and Gautrin,
1990; Papaleo et al., 2011; Seeber et al., 2009; Toppila et al., 2006;
Triebig et al., 1989; Vodička et al., 1995).
Inhalation of tobacco smoke, off-gassing of building materials and
consumer products, and vehicle and industrial emissions accounts for
over 90% of styrene exposure in the general population (ATSDR, 2011;
USEPA, 1994; IARC, 2002; CDC, 2013). Exposure via dermal contact is
typically limited to occupational settings, and internal dose due to
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ingestion from food and water is considered negligible. Among smo-
kers, cigarettes are considered the dominant source of styrene exposure,
and smoking is the single most important individual predictor of human
exposure to styrene (ATSDR, 2010; Adgate et al., 2004; Ashley et al.,
1994, 1995; Cohen et al., 2002; Wallace, 1986; Wallace et al., 1987;
Chambers et al., 2011). Styrene is released into the air from automobile
exhaust, cigarette smoke, photocopiers and printers, and industries
using or manufacturing styrene. The Gulf region is home to a prolific
petrochemical industry, many styrene-emitting industries, and over half
of all U.S. styrene production (ATSDR, 2010; NTP, 2014), potentially
exposing Gulf residents to a high intensity of environmental styrene
emissions.
Styrene is commonly detected in urban air, near industrial sites and
landfills, and in high traffic areas, although typically at levels sub-
stantially lower than in occupational settings. Rural and suburban air
generally contains lower concentrations of styrene than urban air
(Miller et al., 1994). In the U.S. general population, daily exposure to
styrene in air is estimated to be 18–54 μg/person (ATSDR, 2010), and
indoor air usually contains higher levels of styrene than outdoor air.
Because the half-life of styrene in blood is approximately 13 h (CDC,
1978), blood styrene measurements reflect recent exposure.
The Agency for Toxic Substances and Disease Registry (ATSDR) has
identified the central nervous system (CNS) as the primary target for
styrene toxicity, with less marked effects in the peripheral nervous
system (PNS) (ATSDR, 2011; Gobba et al., 1995). Like many other
volatile organic compounds, styrene monomer is a CNS depressant with
anesthesia-like properties (IARC, 2002; Tormoehlen et al., 2014). Acute
solvent-induced neurotoxicity, including that caused by styrene, is
characterized by symptoms of acute intoxication, commonly described
as a feeling of drunkenness. Long term exposures at levels found in
occupational settings have been associated with chronic adverse neu-
rotoxic effects. Occupational studies demonstrate styrene-induced
neurotoxicity, from both acute and chronic inhaled exposure among
highly-exposed workers. Symptoms include feeling “drunk” and tired-
ness (Checkoway et al., 1992), impaired vision (Gobba et al., 1995;
Kishi et al., 2001), vestibular dysfunction (Toppila et al., 2006),
headaches (Edling et al., 1993), delayed reaction time (Jegaden et al.,
1993; Tsai and Chen, 1996), impaired attention and memory (Cherry
and Gautrin, 1990), hearing deficits (Johnson et al., 2006), diminished
nerve conduction velocity (Cherry and Gautrin, 1990; Murata et al.,
1994; Rosén et al., 1978; Stetkarova et al., 1993; Matikainen et al.,
1993), and abnormal electroencephalogram results (Matikainen et al.,
1993; Seppäläinen and Härkönen, 1976). Similar effects have been
observed at lower occupational airborne exposure levels, ranging from
10 to 30 ppm, in most (Papaleo et al., 2011; Gobba et al., 1995; Edling
et al., 1993; Jegaden et al., 1993; Tsai and Chen, 1996; Mutti et al.,
1984; Flodin et al., 1989; Tsai et al., 1997; Viaene, 2001), though not
all (Triebig et al., 1989; Rebert and Hall, 1994), studies.
The human health effects of chronic styrene exposure at typical
environmental levels remain largely unknown (Cohen et al., 2002). We
set out to assess the associations between two metrics of styrene ex-
posure - estimated ambient concentrations and measured blood levels -
and self-reported neurologic symptoms among Gulf state residents.
Quantifying the association between environmental styrene exposure
and highly sensitive, but non-specific, neurologic symptoms may lend
insight into early manifestations of environmentally induced neuro-
toxicity due to chronic exposures at levels insufficient to cause clinically
apparent toxicity.
2. Methods
2.1. Study design and participants
We used data from the Gulf Long-term Follow-up Study (GuLF
STUDY), a prospective cohort of adults (ages 21 and older) who par-
ticipated in oil spill response activities and others who received safety
training, but were not hired, following the 2010 Deepwater Horizon
disaster. A detailed description of this study is available elsewhere
(Kwok et al., 2017). Of the 25,848 English- or Spanish-speaking GuLF
STUDY participants living in the Gulf region (Alabama, Florida,
Louisiana, Mississippi, and Texas) at enrollment, 24,903 reported ad-
dresses that were successfully geocoded to a 2010 U.S. Census tract.
From this sample of participants with known residential locations, we
excluded participants with any missing neurologic symptom informa-
tion (n=304), missing demographic characteristics (n= 573), and
missing covariate information (n=201), leaving 23,825 eligible par-
ticipants. Because autonomic and peripheral neuropathy are known
complications of diabetes (Freeman, 2014), we further restricted the
study sample to participants with no self-reported physician diagnosis
of diabetes (exclude 1825 diabetics and 38 with missing diagnosis in-
formation), resulting in a final analytic sample of 21,962.
Approximately 2–3 years after the oil spill (May 2012–July 2013), a
subset of GuLF STUDY participants living in the Gulf region (N=1055)
were enrolled in the Chemical Biomonitoring Study (CBS) (Engel et al.,
2017; Werder et al., 2018). CBS participants provided an extra blood
sample for measuring styrene and other compounds and completed a
questionnaire about usual and recent exposures and exposure oppor-
tunities.
Ultimately, 994 participants provided blood samples sufficient for
quantification of styrene levels. Of those, we excluded 20 participants
missing neurologic symptom information, nine with incomplete de-
mographic characteristics, and four individuals missing other covariate
information, leaving 961 eligible participants. We then excluded known
diabetics (n=86 of the 1825 diabetics from the parent study) or those
missing diagnosis information (n= 1), for a final analytic sample of
874.
Participants provided written informed consent, and the
Institutional Review Board of the National Institute of Environmental
Health Sciences approved this study.
2.2. National Air Toxics Assessment
The United States Environmental Protection Agency (EPA) 2011
National-scale Air Toxics Assessment (NATA) (USEPA, 2011a) evalu-
ates 180 air toxics across the United States using emissions inventories,
dispersion modeling, photochemical modeling, exposure modeling, and
toxicity analyses. NATA generates annual average ambient air toxic
concentrations (μg/m3) for each U.S. census tract. We employed NATA
styrene estimates as indicators of typical environmental exposure by
mapping each participant's geocoded home location to a corresponding
2010 U.S. census tract. Geocodes were based on self-reported home
address at enrollment. The 2011 NATA estimated annual average am-
bient styrene concentration corresponding to an individual's home
census tract was applied as a surrogate of usual ambient styrene ex-
posure for each cohort member residing in the Gulf region.
2.3. Blood styrene measurement
Blood collection tubes containing potassium oxalate and sodium
fluoride anticoagulant were used to collect 10mL of blood for styrene
measurement. Tubes and stoppers were pre-treated by the Centers for
Disease Control and Prevention (CDC) laboratory to remove VOC re-
sidues to minimize pre-collection contamination (Chambers et al.,
2008; Chambers et al., 2005). Samples were stored in a 4 °C refrigerator
prior to being shipped overnight on cold packs in biweekly batches to
the Division of Laboratory Sciences, National Center for Environmental
Health, CDC in Atlanta, Georgia, for analysis of VOCs. Analysis of
styrene followed standard CDC procedures, using equilibrium head-
space solid-phase micro-extraction with benchtop gas chromatography/
mass spectrometry (Blount et al., 2006; Chambers et al., 2006). The
laboratory provided actual measured values below the limit of detec-
tion (LOD) (0.03 ng/mL).
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2.4. Neurologic symptoms
Health information, including questions about neurologic symp-
toms, was collected at enrollment via Computer Assisted Telephone
Interview (CATI) during the baseline interview. All participants were
asked to report how often they experienced dizziness, lightheadedness,
vision impairment, numbness, tingling, stumbling while walking,
headaches, and fatigue during the preceding 30 days. Three additional
episodic outcomes, i.e., seizures, vomiting, and insomnia, were added to
the questionnaire after data collection was underway. These latter
outcomes were not combined with other symptoms for evaluation of
“any” neurologic symptom or symptom clusters because their enu-
meration in the study population is incomplete (i.e., those people who
completed the enrollment interview prior to the inclusion of questions
about seizures, vomiting, and insomnia did not have the opportunity to
report them). We did, however, analyze these additional symptoms
individually among the subgroup of participants who had the oppor-
tunity to report them.
Frequency of most symptoms was reported as: all of the time, most of
the time, sometimes, rarely, or never. Symptoms were classified as a
binary indicator of the ‘presence’ (all or most of the time) or ‘absence’
(sometimes, rarely, or never) of occurrence. Seizures, vomiting and
insomnia were reported as: every day, several times a week, once a week,
rarely, or never. We applied a lower threshold for the reporting of epi-
sodic symptoms because the relative frequency of their occurrence is
expected to be lower, as compared with potentially ongoing symptoms.
Accordingly, the presence of vomiting included responses of once a
week or more, and the presence of seizures included reporting a seizure
at any point during the 30 days.
2.5. Statistical analysis
We used multivariate log-binomial regression to estimate pre-
valence ratios and corresponding 95% confidence intervals (PR, 95%
CI) for the cross-sectional associations between modeled and measured
styrene levels and neurologic symptom prevalence. We evaluated as-
sociations between (i) ambient styrene concentration estimates (μg/m3)
and neurologic symptoms among all eligible study participants residing
in the Gulf region (N=21,962), and (ii) blood styrene concentration
(ng/mL) and neurologic symptoms among CBS participants (n=874).
We also examined the distributions of NATA estimated ambient con-
centrations and log-transformed blood styrene levels to determine re-
levant rank-based exposure metrics.
We analyzed symptom clusters as primary outcomes. Based on re-
sults of a latent class analysis of symptom correlations among all re-
ported symptoms (data not shown), we identified two neurologic
clusters (i.e., CNS and PNS). The CNS cluster included dizziness,
headache, nausea, sweating, and palpitations. The PNS cluster included
tingling and numbness in the extremities, blurred vision, and stumbling
while walking. For main analyses, we separately examined associations
between styrene level and the presence of any neurologic symptom, any
CNS symptom, more than one CNS symptom, any PNS symptom, and
more than one PNS symptom. We included sweating and palpitations in
our identification of CNS symptoms, based on results of the latent class
analysis. We did not, however analyze these symptoms as individual
neurologic outcomes in any other analyses because of their non-specific
nature and lack of precedent in neurotoxicity literature. We further
conducted sensitivity analyses excluding sweating and palpitations
from the CNS symptom cluster. In secondary analyses, we examined
associations between styrene levels and each individual neurological
symptom in a separate model.
All models were adjusted for sex (male, female), age (< 30,
30–45,> 45), season (spring, summer, fall, winter), race (white, black,
other), educational attainment (< high school, high school graduate or
equivalent, some college, college graduate or more), employment status
(currently working, not working), alcohol drinking (current, former/
never), and self-reported smoking (current, former/never). In models
assessing associations with blood styrene, we accounted for the dura-
tion of time (days) between enrollment (symptom ascertainment) and
the date of blood styrene collection two ways. In primary analyses, we
adjusted for the duration, and in sensitivity analyses, we restricted to
participants within the median lag between enrollment and blood
styrene collection (100 days). For statistical analyses, we used all
measured blood styrene values, including the measured values below
the LOD (Whitcomb and Schisterman, 2008). Covariates were selected
based on directed acyclic graph analysis (Greenland et al., 1999) of the
theoretical relationship between styrene exposure and neurologic
symptoms. Covariate information was obtained during the enrollment
interview.
We conducted several sensitivity analyses, examining the impact of
spatial clustering, smoking, co-exposures, oil spill cleanup, depression,
chronic conditions, amount of overall symptom reporting (i.e., number
of symptoms reported), sex, race, and socioeconomic status on observed
associations. To address concern over possible effects due to spatial
clustering in the study population, we used generalized estimating
equations to specify a random effect of census tract (the unit of ag-
gregation for ambient styrene estimates generated by NATA) for all
ambient styrene analyses.
Given that smoking is a principal source of non-occupational styrene
exposure, we evaluated smoking by adjusting for current, former, and
never smokers distinctly, as well as restricting analyses to never smo-
kers.
For co-exposure analyses, we additionally adjusted for benzene and
toluene, in separate models. Ambient benzene and toluene estimates
were abstracted from NATA 2011, and blood benzene and toluene le-
vels were measured on the same panel as styrene. In ambient analyses,
we additionally adjusted for ambient particulate matter (PM 2.5).
Annual census tract estimates of PM 2.5 were obtained from the EPA
fused Downscaler Model 2011 (USEPA, 2011b).
Although oil spill cleanup is not a known source of styrene ex-
posure, we conducted sensitivity analyses assessing effects of oil spill
cleanup due to its importance in defining this study population. To that
end, we conducted stratified analyses of cleanup workers and non-
workers separately and evaluated the statistical interaction between
styrene levels and cleanup worker status.
Depression was defined based on self-reported physician diagnosis
at enrollment, and we conducted stratified analyses comparing asso-
ciations between participants who did and did not report depression. In
addition to evaluating depression, we examined the influence of other
chronic conditions on observed associations. We simultaneously ad-
justed for any reported cancer, emphysema, and asthma, as well as
separately evaluating the impact of adjusting for diabetes instead of
excluding participants reporting a diabetes diagnosis. Participants were
asked about frequency of 18 non-neurologic symptoms in addition to
those included here as indicative of potential neurological effects. We
tried to account for symptom over-reporting by making exclusions for
different thresholds of number of symptoms reported, adjusting for
total number of symptoms reported, excluding participants who re-
ported excessive recent hair loss, which is not believed to be related to
any of the exposures under investigation, and restricting analyses to
participants reporting only neurologic symptoms.
We evaluated effect modification by both sex and race using inter-
action terms between exposure and the modifier of interest, as well as
running stratified models for the subgroups identified. To address so-
cioeconomic status, we adjusted for income and self-reported concerns
over affording housing and food.
We also completed analyses specifying different exposure contrasts
for both ambient and blood styrene levels and repeated all main ana-
lyses restricting to the subgroup of participants who had the opportu-
nity to report on the three symptoms (seizures, vomiting, and insomnia)
that were added later.
All statistical analyses were conducted in SAS 9.4 (Cary, NC, USA).
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3. Results
This cohort is predominantly male (80.6%), younger than 45 years
(58.8%), and overweight (40.4%) or obese (31.5%) (Table 1A). Ap-
proximately one-third of participants are current smokers, and 75.6%
completed at least one day of oil spill response or cleanup work. Par-
ticipants who provided blood specimens for CBS were less likely to be
employed (52.9% vs. 62.7%) and more likely to have worked on oil
spill response (84.9% vs. 75.6%), compared to the full cohort of Gulf
region residents (Table 1B). The CBS also has a higher proportion of
nonwhite participants than the overall sample (49.8% compared to
37.6%), and fewer college graduates (12.0% compared to 18.5%).
African Americans are disproportionately likely to live in areas with
higher estimated ambient styrene levels, representing 18.0% of the
lowest quartile and 42.6% of the highest quartile population
(Table 1A). The distribution of demographic characteristics is similar
between participants who were excluded due to incomplete covariate
information and participants who were included in the modeled sam-
ples.
Based on the distribution of ambient styrene concentrations among
Gulf region participants (Fig. 1), we modeled neurologic symptoms in
relation to quartiles of ambient estimated styrene. The distribution
features a prominent right skew, with the top quartile ranging from
0.03 to 1.70 μg/m3 styrene. The referent exposure group (first quartile)
experienced estimated ambient styrene levels up to 0.01 μg/m3 styrene.
When comparing airborne styrene concentrations in the Gulf region to
the entire U.S., the distributions are very similar with some slight
variability in the top 5% of census tracts (data not shown). The dis-
tribution of blood styrene concentration has a less pronounced right
skew (Fig. 1) and the sample size is relatively small. We elected to di-
chotomize blood concentrations at the median value, 0.067 ng/mL
styrene. We did not observe significant correlations between estimated
ambient and measured blood styrene levels.
Increasing ambient styrene concentration was associated with the
presence of any neurologic symptom, with statistically significant
Table 1A
Demographic characteristics of participants living in the Gulf region (N=21,962) by estimated ambient styrene levels.
Characteristic N % Estimated styrene, quartiles (%)
Q1 Q2 Q3 Q4
Sex Female 4259 19.4 17.6 19.0 20.0 21.1
Male 17,703 80.6 82.4 81.0 80.0 78.9
Age, years < 30 4685 21.3 20.8 19.8 21.4 23.3
30–45 8241 37.5 35.3 36.1 38.2 40.7
> 45 9036 41.1 43.9 44.2 40.4 36.1
Season of enrollment Spring 6104 27.8 28.0 26.6 27.7 28.8
Summer 5329 24.3 24.9 25.1 23.5 23.5
Fall 4968 22.6 21.9 23.8 23.2 21.6
Winter 5561 25.3 25.1 24.5 25.6 26.1
Race White 13,723 62.5 70.9 70.1 60.6 48.2
Black 6051 27.6 18.0 20.7 29.2 42.6
Other 2188 10.0 11.2 9.2 10.2 9.2
Education <High school 4072 18.5 23.6 17.1 17.0 16.4
High school graduate 7285 33.2 36.9 31.6 31.1 33.0
Some college 6554 29.8 26.4 31.7 31.2 30.1
≥College graduate 4051 18.5 13.1 19.5 20.7 20.6
Work status Employed 13,780 62.7 63.9 63.5 63.0 60.5
Unemployed 8182 37.3 36.1 36.5 37.0 39.5
Current drinker Yes 16,441 74.9 72.3 76.1 76.1 75.0
No 5521 25.1 27.7 23.9 23.9 25.0
Current smoker Yes 7514 34.2 36.8 34.1 34.1 31.7
No 14,448 65.8 63.2 65.9 65.9 68.3
Body Mass Index, kg/m2 ≤Normal (< 25) 6173 28.1 26.8 28.7 28.9 28.0
Overweight (25–<30) 8877 40.4 39.5 41.7 40.5 40.0
Obese (≥30) 6912 31.5 33.7 29.5 30.6 31.9
Oil spill response worka ≥1 day 16,599 75.6 71.9 75.1 77.1 78.3
None 5363 24.4 28.1 24.9 22.9 21.7
a Participants reported working on Deepwater Horizon oil spill cleanup for at least one day in 2010–2011.
Table 1B
Demographic characteristics of participants in the Chemical Biomonitoring
Study (CBS, N=874) by measured blood styrene levels.
Characteristic N % Blood styrene (%)
≤Median >Median
Sex Female 220 25.2 27.2 23.2
Male 654 74.8 72.8 76.8
Age, years < 30 194 22.2 23.3 21.1
30–45 343 39.2 35.7 42.8
> 45 337 38.6 41.0 36.1
Season of enrollment Spring 174 19.9 20.4 19.4
Summer 198 22.7 26.9 18.3
Fall 185 21.2 20.4 22.0
Winter 317 36.3 32.3 40.3
Race White 439 50.2 51.8 48.6
Black 368 42.1 38.5 45.8
Other 67 7.7 9.7 5.6
Education <High school 179 20.5 17.9 23.2
High school
graduate
340 38.9 36.4 41.4
Some college 250 28.6 29.4 27.8
≥College graduate 105 12.0 16.3 7.6
Work status Employed 462 52.9 58.4 47.2
Unemployed 412 47.1 41.6 52.8
Current drinker Yes 598 68.4 67.4 69.4
No 276 31.6 32.6 30.6
Current smoker Yes 261 29.9 12.7 47.4
No 613 70.1 87.3 52.6
Body Mass Index, kg/
m2
≤Normal (< 25) 249 28.5 22.4 34.7
Overweight
(25–< 30)
333 38.1 39.6 36.6
Obese (≥30) 292 33.4 38.0 28.7
Oil spill response
worka
≥1 day 742 84.9 83.5 86.3
None 132 15.1 16.5 13.7
a Participants reported working on Deepwater Horizon oil spill cleanup for at
least one day in 2010–2011.
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associations at each quartile (Table 2, Fig. 2). For any CNS symptom,
multiple CNS symptoms, any PNS symptom, and multiple PNS symp-
toms, the top quartile of estimated styrene was positively and sig-
nificantly associated with reporting neurologic symptoms. The stron-
gest association we observed among the cluster analyses was a 26%
increase in prevalence of multiple CNS symptoms among those in the
top quartile of ambient estimated styrene concentration (PR, 1.26; 95%
CI: 1.15, 1.38). We observed significant linear trends (p-value < 0.01)
between styrene quartiles and each of the symptom clusters (Table 2).
Upon further examination in stratified analyses, we observed the
strongest associations among non-White participants, with African
Americans and those identifying as ‘Other races’ driving most associa-
tions between estimated ambient styrene and neurologic symptom
clusters (Fig. 3). This heterogeneity persisted, and results were un-
changed, in models adjusted for income among the subset of partici-
pants for whom income is known (n=19,941).
The prevalence of individual neurologic symptoms ranged from
1.8% for seizures to 16.1% for fatigue, with 30.8% of participants re-
porting at least one of the original neurologic symptoms (excluding
vomiting, seizure, and insomnia) (Table 2). Among those participants
who were also asked about the additional symptoms added later
(n=16,536), the prevalence of any original neurologic symptom was
33.0% (and 38.0% including vomiting, seizure, and insomnia). The
highest quartile of ambient estimated styrene was positively and sig-
nificantly associated with each individual neurologic symptom. Many
of the associations with individual symptoms demonstrated clearly in-
creasing exposure-response relationships across quartiles of estimated
styrene, and linear trends were significant (p < 0.01) for all symptoms.
In analyses of blood styrene above the median concentration and
neurologic symptom clusters, we observed small to modest, non-
significant positive associations for any PNS and multiple PNS symp-
toms (Table 3). The strongest association was a 37% increase in pre-
valence of multiple PNS symptoms, which was of borderline
significance (PR, 1.37; 95% CI: 0.99, 1.89). Among CBS participants,
seizure was the least common symptom (2.8%) and fatigue was the
most prevalent (24.7%). Although associations between blood styrene
and symptom clusters were generally not apparent, we did observe a
noteworthy, albeit nonsignificant, positive association for the in-
dividual symptoms of dizziness (PR, 1.23; 95% CI: 0.77, 1.96), and a
significant association for nausea (PR, 1.78; 95% CI: 1.04, 3.03)
(Table 3).
Our findings were robust to exclusions and adjustments made in
sensitivity analyses. We did not detect changes in results due to spatial
clustering when we modeled associations specifying a random effect for
census tract in models. These models, however, demonstrated some
minor losses in precision. When restricting to never smokers, we ob-
served stronger effects compared to those detected in the overall po-
pulation. Accounting for oil spill cleanup work did not impact results,
with interpretations unchanged whether models were adjusted for or
stratified by cleanup participation. The interaction between styrene
levels and cleanup work was consistently statistically non-significant.
Likewise, the interaction between styrene levels and sex was non-sig-
nificant. Point estimates were similar between men and women, al-
though trends were more apparent in men due to improved precision
from a larger sample size. Additional adjustments made to capture
variability in socioeconomic status, such as income and concerns over
affording housing and food, did not change results. Small sample sizes
precluded our ability to evaluate heterogeneity by race in blood styrene
analyses. Subgroup analyses were underpowered and unstable, with
incomplete model convergence.
Spearman correlation coefficients between estimated ambient con-
centrations of styrene and each of benzene, toluene, and PM 2.5 were
0.69, 0.76, and 0.43, respectively. Associations between styrene and
neurologic symptom clusters were stronger in models adjusted for es-
timated ambient benzene or toluene (Supplemental Fig. 1). Adjusting
for PM 2.5 had little effect, yielding estimates that were virtually
identical to our primary results. Adjustment for blood levels of benzene
and toluene did not meaningfully impact results for blood styrene ex-
posure analyses (data not shown).
To evaluate the effect of depression on symptom reporting, we es-
timated associations separately for participants who reported a diag-
nosis of depression (n= 3069, 14%) and those who did not
Fig. 1. Probability density of styrene concentrations
in air (N=21,962) and blood (N=874).
Ambient styrene concentrations are National Air
Toxics Assessment (NATA) 2011 modeled estimates
of annual average concentrations (μg/m3) at the
census tract level.
Blood styrene exposure concentrations (ng/mL) are
measured from a single blood draw obtained in the
participant's home.
Values at the top of reference lines indicate exposure
concentrations; labels at the bottom of reference
lines indicate locations in the exposure distribution:
P25, 25th percentile; P50, 50th percentile; P75, 75th
percentile; P90, 90th percentile; P95, 95th percen-
tile; Max, maximum value.
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(n= 18,805, 86%). Associations among participants without depres-
sion, representing the majority of the sample, were similar to overall
results (Supplemental Fig. 2). Similarly, adjustment for a range of
chronic conditions (diabetes, cancer, asthma, emphysema, and obesity)
did not elicit changes in overall results. Neither excluding participants
who reported a total number of symptoms exceeding a range of
thresholds (e.g. the 95th percentile, or 12 symptoms), nor adjusting for
total number of symptoms reported, had an appreciable impact on
observed associations between ambient styrene and neurologic out-
comes.
Restricting the duration of time between enrollment and blood draw
to below the median (100 days) attenuated some associations between
blood styrene and CNS symptoms slightly but did not meaningfully
change associations. Neurologic effects of blood styrene were un-
changed between models that were adjusted and unadjusted for the
duration of time between enrollment and blood draw. Results were
generally similar in analyses using other exposure contrasts for both
estimated airborne and measured blood styrene levels (e.g. tertiles,
quintiles, 90th percentile, etc.), although risk estimates became more
unstable as exposure groups became smaller. Excluding sweating and
palpitations from the CNS symptom cluster did not meaningfully
change results, though most associations were slightly stronger using
this reduced CNS symptom cluster.
When we repeated analyses for clusters, as well as individual
symptoms, among the subgroup of participants who completed the in-
terview after questions about seizures, insomnia, and vomiting were
added, results were virtually identical to originally reported associa-
tions. Indeed, because the order in which participants were enrolled in
the study was largely random, we have no reason to suspect that in-
dividuals who responded before the additional symptoms were in-
cluded would be meaningfully different from those who responded after
their inclusion.
Table 2
Associations between estimated ambient styrene concentration and individual neurologic symptoms (N=21,962).
Outcome Prevalence, N (%) Ambient styrene PR (95% CI) p for trend
Any neurologic symptom 6759 (30.8) Q2 1.08 (1.03, 1.14) 0.00003
Q3 1.07 (1.01, 1.12)
Q4 1.12 (1.07, 1.18)
Any CNS symptoma 4690 (21.4) Q2 1.05 (0.99, 1.12) < 0.00001
Q3 1.11 (1.05, 1.18)
Q4 1.17 (1.11, 1.25)
≥ 2 CNS symptoms 2037 (9.3) Q2 1.12 (1.01, 1.24) < 0.00001
Q3 1.16 (1.05, 1.28)
Q4 1.26 (1.15, 1.38)
Dizziness 1468 (6.7) Q2 1.03 (0.91, 1.17) < 0.00001
Q3 1.12 (1.00, 1.26)
Q4 1.33 (1.19, 1.48)
Nausea 1046 (4.8) Q2 1.04 (0.90, 1.20) 0.007
Q3 0.96 (0.83, 1.11)
Q4 1.24 (1.09, 1.41)
Headache 3121 (14.2) Q2 1.10 (1.02, 1.20) < 0.00001
Q3 1.18 (1.09, 1.27)
Q4 1.21 (1.12, 1.30)
Any PNS symptomb 4014 (18.3) Q2 1.09 (1.01, 1.17) < 0.00001
Q3 1.06 (0.99, 1.14)
Q4 1.16 (1.09, 1.25)
≥ 2 PNS symptoms 2429 (11.1) Q2 1.09 (0.99, 1.20) 0.0002
Q3 1.14 (1.04, 1.24)
Q4 1.19 (1.08, 1.30)
Tingling/Numbness 3146 (14.3) Q2 1.09 (1.00, 1.18) 0.0001
Q3 1.10 (1.01, 1.19)
Q4 1.18 (1.09, 1.28)
Stumbling 739 (3.4) Q2 1.20 (1.01, 1.44) 0.0002
Q3 1.20 (1.01, 1.43)
Q4 1.39 (1.18, 1.64)
Blurred vision 1656 (7.5) Q2 1.16 (1.03, 1.31) < 0.00001
Q3 1.18 (1.04, 1.32)
Q4 1.43 (1.27, 1.59)
Fatigue 3529 (16.1) Q2 1.13 (1.04, 1.22) 0.001
Q3 1.07 (0.99, 1.16)
Q4 1.16 (1.08, 1.25)
Insomniac 1552 (13.8) Q2 1.19 (1.05, 1.35) 0.001
Q3 1.20 (1.05, 1.36)
Q4 1.25 (1.10, 1.42)
Vomitc 1363 (9.3) Q2 1.18 (1.03, 1.35) 0.001
Q3 1.21 (1.06, 1.38)
Q4 1.24 (1.09, 1.41)
Seizurec 263 (1.8) Q2 1.14 (0.82, 1.59) 0.001
Q3 1.20 (0.87, 1.65)
Q4 1.62 (1.20, 2.19)
Models adjusted for sex, age, season, race, education, employment status at enrollment, alcohol drinking status at enrollment, and smoking status at enrollment.
Prevalence indicates total prevalence in the study sample (all estimated styrene levels).
Ambient styrene quartiles are based on National Air Toxics Assessment (NATA) 2011 estimates of annual average concentrations at the census tract level; referent
group is the lowest quartile (not shown in table). Q2, second quartile; Q3, third quartile; Q4 fourth (highest) quartile.
a CNS symptoms: dizziness, headache, nausea, sweating, palpitations.
b PNS symptoms: tingling/numbness, blurred vision, and stumbling.
c Sample sizes vary for insomnia (n=11,236), vomiting (n=14,591), and seizure (n= 14,591) because they were added to the interview after data collection
was underway, and they are therefore ineligible for inclusion in symptom clusters (any neurologic/CNS/PNS).
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Fig. 2. Associations between estimated ambient styrene concentration and neurologic symptom clusters (N= 21,962).
Models adjusted for sex, age, season, race, education, employment status at enrollment, alcohol drinking status at enrollment, and smoking status at enrollment.
Estimated ambient styrene quartiles are based on National Air Toxics Assessment (NATA) 2011 estimates of annual average concentrations at the census tract level;
referent group is the lowest quartile (not shown on figure). Q2, second quartile; Q3, third quartile; Q4 fourth (highest) quartile.
CNS symptoms include: dizziness, headache, nausea, sweating, and palpitations.
PNS symptoms include: tingling/numbness, blurred vision, and stumbling.
Fig. 3. Associations between estimated ambient styrene concentration and neurologic symptom clusters, stratified by race (N=21,962).
Models adjusted for sex, age, season, education, employment status at enrollment, alcohol drinking status at enrollment, and smoking status at enrollment.
Estimated ambient styrene quartiles are based on National Air Toxics Assessment (NATA) 2011 estimates of annual average concentrations at the census tract level;
referent group is the lowest quartile (not shown on figure). Q2, second quartile; Q3, third quartile; Q4 fourth (highest) quartile.
CNS symptoms include: dizziness, headache, nausea, sweating, and palpitations.
PNS symptoms include: tingling/numbness, blurred vision, and stumbling.
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4. Discussion
To our knowledge, this study was the first to assess subclinical
neurotoxicity of styrene at environmental levels relevant to the general
population. We observed consistent, positive relationships between
increasing ambient estimated styrene levels and neurologic symptoms.
Almost all associations were statistically significant, and a monotonic
exposure-response was evident for each outcome. Although associations
between blood styrene and neurologic symptom clusters were generally
not apparent, we did observe suggestive effects for the PNS cluster and
some individual symptoms (dizziness and nausea).
Among the analyses of estimated ambient styrene, we observed
consistent associations with an unambiguous exposure-response and
significant linear trends for the CNS cluster. These findings are sup-
ported by ATSDR's report identifying the CNS as the primary target of
styrene toxicity (ATSDR, 2010), as well as increased mortality from
diseases of the CNS, especially epilepsy, associated with styrene ex-
posure in a cohort study of reinforced-plastics industry workers (Welp
et al., 1996).
In race-stratified analyses of ambient styrene and symptom clusters,
associations were attenuated in White participants and strengthened
among participants identifying as African American and Other races.
We suspect that this heterogeneity is due, at least in part, to un-
measured confounding by socioeconomic status. This disparity may
operate through cultural differences in symptom reporting, differential
access to healthcare, unmeasured styrene exposure opportunities, and
other residual socioeconomic inequalities. Consistent with previous
research demonstrating that census tracts with higher proportions of
racial minority and low-income populations tend to have higher NATA
concentrations of air toxics (Apelberg et al., 2005; Huang et al., 2017),
African Americans in our study were most likely to live in high styrene
census tracts and report lower incomes. We hypothesize that non-White
participants in the present study may experience increased styrene
exposure due to lower indoor air quality and increased proximity to
intermittent source emissions that are not captured by NATA estimates.
Further, there is evidence that synergistic health effects of social and
physical environmental conditions, such as living in communities
characterized by both elevated chemical exposures and social stressors,
may result in increased health disparities (Clougherty et al., 2007).
When examining individual neurologic symptoms, we observed the
strongest associations for ambient styrene with reported seizures,
blurred vision, stumbling, dizziness, and insomnia. Symptoms with the
strongest evidence for styrene-induced neurotoxicity at occupational
levels include blurred or distorted vision (Kishi et al., 2001; Campagna
et al., 1995, 1996; Iregren et al., 2005; Lomax et al., 2004; Paramei
et al., 2004), dizziness or lightheadedness (Triebig et al., 1989; Edling
et al., 1993; Flodin et al., 1989), headaches (Checkoway et al., 1992;
Edling et al., 1993; Viaene, 2001), and fatigue (Checkoway et al., 1992;
Edling et al., 1993; Flodin et al., 1989; Viaene, 2001). Less consistent
associations have been reported for vestibular impairment (Viaene,
2001), tingling and numbness (Seeber et al., 2009; Edling et al., 1993;
Tsai and Chen, 1996), seizures (Tsai and Chen, 1996; Bolla et al., 1995),
and insomnia (Ritchie et al., 2001). Despite much lower ambient
styrene levels in our study than those present in occupational settings,
our results are generally consistent with these findings.
Blood styrene levels among CBS participants were two to three
times higher than those measured in the National Health and Nutrition
Examination Survey, for smokers and nonsmokers alike. Occupational
styrene exposure levels are typically eight to twelve times higher than
those measured in CBS. We observed suggestive associations of blood
styrene concentration in relation to dizziness, nausea, and having
multiple PNS symptoms. These effect estimates were large in magni-
tude, but some lacked precision due to the sample size and frequency of
symptom reporting.
Having multiple PNS symptoms was associated with both ambient
and blood concentrations of styrene. Dizziness and nausea also de-
monstrated some consistency between elevated ambient and blood
styrene. Differences in associations by exposure measure may be attri-
butable to the relevant temporal window each metric captures.
Measured blood styrene generally reflects the previous 24 h, whereas
NATA estimated concentrations are annual averages thought to reflect
longer term levels. Because blood samples were drawn, on average,
100 days after symptom information was collected, resulting exposure
misclassification is especially likely to have limited our ability to detect
significant associations with blood styrene.
Our study is the first to investigate whether neurologic effects ob-
served among highly exposed occupational populations are also ob-
served among individuals with lower levels of styrene exposure more
typical of the general population. Recent environmental studies eval-
uating effects of simultaneous exposure to multiple hazardous air pol-
lutants (HAPs) have documented associations between environmental
styrene and clinical neurologic outcomes. In studies evaluating modeled
ambient concentrations of a variety of HAPs, styrene was associated
with increased risk of autism spectrum disorder (Kalkbrenner et al.,
2010; Talbott et al., 2015) and amyotrophic lateral sclerosis (Malek
et al., 2015). These results implicate low-level, chronic styrene ex-
posure as a possible public health problem. However, a cross-sectional
analysis of blood VOCs and neurobehavioral testing found a general
lack of significant adverse effects, with the exception that a mixture of
BTEX and styrene was modestly associated with slower reaction time
(Liu and Jia, 2015).
Studies in humans and experimental in vitro and in vivo animal
models have attempted to determine the mode of action for styrene
neurotoxicity, with a dopaminergic mechanism gaining traction (Costa,
1996), but explanations remain speculative. Several studies suggest that
styrene exposure alters dopamine metabolism, marked by decreased
dopamine levels and increased dopamine receptors in rodents and hu-
mans (Gagnaire et al., 2006; Jarry et al., 2002; Mutti and Smargiassi,
Table 3
Associations between blood styrene concentration and individual neurologic
symptoms (N=874).
Outcome Prevalence, N (%) PR (95% CI)
Any neurologic symptom 434 (49.7) 1.01 (0.88, 1.16)
Any CNS symptoma 274 (31.4) 0.97 (0.81, 1.17)
≥2 CNS symptoms 128 (14.7) 1.10 (0.79, 1.54)
Dizziness 90 (10.3) 1.23 (0.77, 1.96)
Nausea 80 (9.2) 1.78 (1.04, 3.03)
Headache 186 (21.3) 1.06 (0.82, 1.37)
Any PNS symptomb 240 (27.5) 1.13 (0.91, 1.42)
≥2 PNS symptoms 152 (17.4) 1.37 (0.99, 1.89)
Tingling/numbness 190 (21.7) 1.07 (0.82, 1.40)
Stumblingc 45 (5.2) –
Blurred vision 105 (12.0) 0.97 (0.68, 1.38)
Fatigue 216 (24.7) 0.96 (0.75, 1.23)
Insomniad 130 (16.7) 0.97 (0.70, 1.35)
Vomitingd 112 (13.1) 1.01 (0.72, 1.44)
Seizurec,d 24 (2.8) –
Models adjusted for sex, age, season, race, education, employment status at
enrollment, alcohol drinking status at enrollment, smoking status at enrollment,
and duration (days) between enrollment and blood draw.
Blood styrene exposure is classified as above the median concentration
(0.067 ng/mL) compared to all measurements below the median concentration.
a CNS symptoms include: dizziness, headache, nausea, sweating, and palpi-
tations.
b PNS symptoms include: tingling/numbness, blurred vision, and stumbling.
Prevalence indicates total prevalence in the study sample (both exposed and
unexposed).
c No effect estimate presented for stumbling, seizure due to lack of model
convergence.
d Sample sizes vary for insomnia (n= 780), vomiting (n=857), and seizure
(n=857) because they were added to the interview after data collection was
underway, and they are therefore ineligible for inclusion in symptom clusters
(any neurologic/CNS/PNS).
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1998). The styrene metabolites phenylglyoxylic acid and mandelic acid
are shown to deplete dopamine in neurologic tissues (Terre'Blanche
et al., 2011). This mechanism is corroborated in blood samples of
styrene-exposed plastics workers for whom prolactin levels are ele-
vated, as prolactin release is chronically inhibited by dopamine
(Luderer, 2004). Consistent with disturbance of the dopaminergic
functions of the brain, styrene exposure potentiates a dose-dependent
decrease in brain dopamine in male rats (Mutti and Smargiassi, 1998).
Styrene also causes cell loss and dopamine depletion in retinas isolated
from female rats (Vettori et al., 2000), supporting the established as-
sociation between occupational styrene exposure and impaired vision
(Gong et al., 2002).
Our study has several strengths, including a large sample size, a
well-characterized, diverse, understudied population, multiple sensitive
measures of neurotoxicity, complementary metrics of exposure, and
findings that were robust to multiple sensitivity analyses.
Neurologic symptoms can reveal subtle impairments in neurologic
function before the occurrence of clinically apparent disease. While less
severe, these symptoms may be more sensitive to lower exposure levels,
longer lasting, and more prevalent in the general population. Self-re-
ported symptoms can provide highly sensitive measures of toxicant-
associated neurotoxicity (Lundberg et al., 1997). Thus, symptom as-
sessment is an appropriate measure to capture the potentially subtle,
widespread neurotoxic effects of the observed environmental styrene
levels.
We assessed two metrics of styrene exposure, one reflecting typical
ambient levels and one reflecting short-term internal burden. Modeling
exposure this way helps address the trade-offs between possible con-
founding bias for blood styrene, and potential measurement error of
NATA ambient styrene estimates (Weisskopf and Webster, 2017). As-
sociations were not entirely consistent between measured blood and
estimated ambient styrene, which may be due to limitations of both
biomarkers and proxy exposure measures, or the temporal windows
they reflect. NATA estimates have been successfully used as measures of
human air pollution exposure in epidemiologic studies of cancer
(Garcia et al., 2015; Symanski et al., 2016; Zhou et al., 2015), asthma
(Stoner et al., 2013), birth defects (Swartz et al., 2015), autism spec-
trum disorder (Kalkbrenner et al., 2010; Talbott et al., 2015; Roberts
et al., 2013), and neurodegenerative diseases (Malek et al., 2015). We
used NATA styrene estimates as indicators of typical environmental
exposure, and blood styrene measurements to capture internal burden
resulting from recent exposures. Blood styrene is a validated biomarker
specific to styrene exposure (CDC, 2013) and it has been used ex-
tensively in occupational research (IARC, 2002), as well as in general
population monitoring (ATSDR, 2010).
Limitations of our study include the use of an estimated annual
average ambient concentration, single blood draw for styrene mea-
surement, and lack of detailed medical treatment and occupational
exposure information. Due to the cross-sectional study design, we
cannot confirm temporality between styrene exposure and the onset of
neurologic symptoms. It is, however, unlikely that the symptoms as-
sessed would lead to the estimated ambient or blood styrene con-
centrations we observed. More relevant to the cross-sectional design
limitation is our inability to distinguish between transient effects due to
acute exposures and persistent neurologic effects of long-term styrene
exposure.
Routine monitoring of ambient styrene in the U.S. does not provide
sufficient temporal or spatial coverage to support exposure interpolation
methods (Li and Heap, 2011; Whitworth et al., 2011; Wong et al., 2004).
NATA remains the only spatially-referenced exposure data source with
sufficient geographic coverage for the Gulf region. We recognize that
using this type of surrogate for typical ambient exposure does not in-
corporate variability in residential history (e.g., duration at the assigned
census tract), daily activity patterns, time spent in/outdoors, or time
spent outside of the residential census tract. Our inability to account for
these factors and other assumptions inherent to an annual average
estimate of air pollution limits interpretation for acute exposure sce-
narios, but NATA data are considered a valid estimation of usual ex-
posure levels. If styrene-associated neurologic effects are the result of
long-term exposure, this type of exposure metric may be better suited to
capturing the associations of interest. Long-term ambient styrene trends
indicate that year-to-year regional variation in concentration is not
substantial, suggesting that the annual average estimate is an appropriate
measure of usual, long-term exposure (Cohen et al., 2002). Stable blood
styrene levels in independent U.S. population samples, measured cross-
sectionally, over a 20-year period corroborate these findings (Ashley
et al., 1994; CDC, 2013; Churchill et al., 2001).
Although we obtained only a single blood measurement from each
individual, the sample size is large for a biomarker-based study. At
occupational exposure levels, biomarkers consistently predict exposure
classification according to job title and occupational styrene-related
activities (Brugnone et al., 1993; Papaleo et al., 2011; Checkoway et al.,
1992; Anttinen-Klemetti et al., 2006; Carbonari et al., 2015; Caro and
Gallego, 2009; Helal and Elshafy, 2013; Liljelind, 2003; Liljelind et al.,
2001; Ong et al., 1994; Serdar et al., 2006; Tranfo et al., 2012). In
general, these biomarkers correlate well with indoor air styrene levels,
but the relationship does not necessarily persist for outdoor air styrene
concentrations. Indeed, we observed limited concordance between
measured blood styrene and NATA estimated concentrations (Werder
EJ, submitted). In occupational studies, the correlation between styrene
in blood and indoor air ranges from 0.62 to 0.94 (Vodička et al., 1995;
Serdar et al., 2006; Vodicka et al., 2003). In a study of low occupational
styrene levels measured in air, blood, and urine, the highest correla-
tions with ambient levels were observed for blood styrene (Ong et al.,
1994).
We lacked the data necessary to account for participants' use of
medical treatments and medication. As such, neurologic symptoms may
have been masked or attenuated by medical treatment, thus increasing
outcome measurement error. We did, however attempt to account for
general health status by evaluating depression, chronic conditions,
Body Mass Index, diabetes, and number of symptoms reported.
Lacking detailed information on styrene-specific occupational ex-
posure opportunities, we assessed reported industry, occupation, and
activity information for participant's recent and longest-held jobs.
Ultimately, occupational styrene exposure opportunities were so rare in
our study population (0.1%), that we concluded that occupational ex-
posures were not appreciably influencing results. Although oil spill
cleanup is not considered a source of occupational styrene exposure, we
did consider the potential fundamental differences between participants
who participated in oil spill cleanup and those who did not. These
analyses did not reveal any impacts of cleanup worker status on the
association between styrene and neurologic symptoms.
Our results provide strong evidence for an association between
ambient styrene exposure and neurologic symptoms, suggesting that
styrene may be neurotoxic at environmental levels relevant to the
general population. These findings were consistent across a wide range
of sensitivity analyses. The relationship between blood styrene ex-
posure and neurologic symptoms was equivocal, but suggestive of an
association for certain endpoints. Although we cannot refute the pos-
sibility of acute effects, these results are more indicative of a relation-
ship between typical cumulative styrene exposure and neurologic ef-
fects. Due to the cross-sectional nature of our study, the temporality of
exposure and outcome is uncertain. While short-term acute intoxication
is typically reversible, ceasing when styrene is cleared from the body,
more concerning for overall health are the potential chronic, subtle but
demonstrable, and irreversible effects that persist after styrene is
cleared from the body (Rosengren and Haglid, 1989). Timing of en-
vironmental styrene exposure and duration of neurotoxic effects may be
an important area of future public health research.
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